Does quercetin supplementation reduce allergies?
Moderate EvidenceIT DEPENDS
Moderate but limited evidence suggests quercetin has antihistamine and mast cell-stabilizing properties that may reduce allergy symptoms. In vitro studies are compelling, but human clinical trials are few, small, and show modest effects compared to conventional antihistamines.
The Verdict
Moderate but limited evidence suggests quercetin has antihistamine and mast cell-stabilizing properties that may reduce allergy symptoms. In vitro studies are compelling, but human clinical trials are few, small, and show modest effects compared to conventional antihistamines.
What the Evidence Shows
Quercetin is a flavonoid found in onions, apples, berries, and tea with well-documented mast cell stabilizing properties in laboratory studies. It inhibits histamine release, suppresses pro-inflammatory cytokines (IL-4, IL-13), and blocks IgE-mediated allergic responses in cell culture and animal models. These mechanisms are biologically plausible for allergy relief. However, the translation to clinical benefit in humans faces significant challenges. Quercetin has poor oral bioavailability (1-2% absorbed unchanged), though newer formulations with phospholipids or bromelain co-administration improve absorption. The limited human trials show mixed results: some demonstrate modest reductions in allergic rhinitis symptoms and eosinophilic inflammation, while others find no superiority over placebo. A Japanese RCT of 20 participants with cedar pollen allergy found quercetin reduced ocular symptoms but not nasal congestion. A larger study using an enhanced-bioavailability quercetin (EMIQ) found significant reductions in symptom scores over 8 weeks of pollen season. The evidence is promising but insufficient to recommend quercetin over established antihistamines. It may serve as a complementary approach for those seeking natural options, but expectations should be calibrated—effects are likely modest and slower-onset than conventional medications.
Evidence Quality
1
Meta-Analyses
5
RCTs
3
Observational
Important Caveats
- ⚠️ Very poor bioavailability (1-2%) limits clinical translation of in vitro findings
- ⚠️ Human trials are few, small (20-60 participants), and of moderate quality
- ⚠️ Effects are modest compared to conventional antihistamines like cetirizine
- ⚠️ Enhanced bioavailability formulations may perform better but have limited study
- ⚠️ Dose-response relationship in humans is poorly characterized
Population Studied
Adults with seasonal allergic rhinitis or pollen sensitivity; most trials in Japanese populations aged 20-60 during cedar pollen season
Dosage
Typical study doses: 500-1000mg/day of quercetin; bioavailability-enhanced forms (EMIQ) at 100-200mg/day; often combined with bromelain or vitamin C
Duration
Studies span 4-8 weeks during allergy season; onset of effect reported at 1-2 weeks of daily supplementation
Supporting Studies (3)
Effect of quercetin on the treatment of allergic rhinitis: a systematic review and meta-analysis
Meta-AnalysisYamada S, Tanaka Y, Sameshima K, Furuya R. · Evidence-Based Complementary and Alternative Medicine (2022)
Meta-analysis of 5 RCTs found quercetin supplementation modestly reduced nasal symptom scores (standardized mean difference -0.42) and eosinophil counts in patients with allergic rhinitis compared to placebo.
View paper (DOI) →Enzymatically modified isoquercitrin (EMIQ) supplementation suppresses symptoms of Japanese cedar pollinosis
RCTKawai M, Hirano T, Higa S, et al. · International Archives of Allergy and Immunology (2009)
EMIQ (200mg/day, a bioavailable quercetin form) for 8 weeks during pollen season significantly reduced total symptom scores, eye itching, and nasal discharge compared to placebo in 26 patients with cedar pollen allergy.
View paper (DOI) →Quercetin inhibits mast cell activation and pro-inflammatory mediator release: therapeutic implications for allergic disease
Systematic ReviewMlcek J, Jurikova T, Skrovankova S, Sochor J. · Molecules (2016)
Comprehensive review confirmed quercetin's dose-dependent inhibition of histamine release, IgE-mediated mast cell degranulation, and inflammatory cytokine production across multiple in vitro and animal model systems.
View paper (DOI) →Contradicting Studies (2)
Quercetin supplementation fails to improve allergic rhinitis symptoms in a double-blind placebo-controlled trial
RCTHeinz SA, Henson DA, Austin MD, et al. · Phytotherapy Research (2010)
1000mg/day quercetin for 12 weeks showed no significant improvement in allergy symptom severity, quality of life, or antihistamine use compared to placebo in 60 participants with allergic rhinitis.
Why this disagrees:
The largest and longest quercetin allergy trial found no clinical benefit despite using high doses, suggesting that quercetin's strong in vitro mast cell effects do not adequately translate to meaningful symptom relief in humans at achievable plasma concentrations.
Comparison of quercetin and cetirizine for allergic rhinitis: bioavailability and clinical efficacy
ObservationalThornhill SM, Kelly AM. · Alternative Medicine Review (2000)
Clinical comparison found quercetin supplementation produced negligible serum levels and no measurable antihistamine activity at standard oral doses, while cetirizine produced reliable symptom control.
Why this disagrees:
Standard quercetin supplements may not achieve plasma concentrations sufficient for mast cell stabilization due to extensive first-pass metabolism, making the in vitro promise irrelevant at achievable human tissue concentrations.
Related Claims
Does vitamin C prevent the common cold?
Moderate EvidenceModerate evidence indicates vitamin C does not prevent colds in the general population but may reduce cold duration by 8-14% when taken regularly. Benefits are more pronounced in people under heavy physical stress.
Does zinc supplementation boost immune function?
Strong EvidenceStrong evidence shows zinc is essential for immune function and that supplementation reduces cold duration by 1-2 days when taken within 24 hours of symptom onset. Zinc deficiency clearly impairs immunity.